Buy ADB-BUTINACA Powder for Advanced Laboratory Research in the USA and Europe

ADB-BUTINACA (systematically designated as N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-1-butyl-1H-indazole-3-carboxamide, N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide, or 1-butyl-N-[(1S)-1-carbamoyl-2,2-dimethylpropyl]indazole-3-carboxamide; CAS Registry Number: 2682867-55-4) represents a critical analytical reference standard within the synthetic cannabinoid receptor agonist (SCRA) class, serving indispensable roles in forensic toxicology, cannabinoid receptor binding assays, and mass spectral library development for European and USA laboratory environments. As a 1-butyl-substituted indazole-3-carboxamide analogue structurally related to ADB-INACA, ADB-BINACA, 5F-ADB, and MDMB-5Br-INACA, this compound is essential for novel psychoactive substance (NPS) monitoring, CB1 and CB2 receptor pharmacology studies, and confirmatory toxicological screening. Roid Chem Store stands as the definitive USA AND European source for this rigorously characterised compound, supplying analytical-grade ADB-BUTINACA powder at 99% purity to research institutions, CROs, and pharmaceutical R&D facilities committed to reproducible, publishable outcomes. Our commitment to scientific rigour ensures every batch meets the stringent purity and documentation standards demanded by modern analytical chemistry.

Uncompromising Purity and Analytical Characterisation

Every batch of ADB-BUTINACA Powder supplied by Roid Chem Store is guaranteed to exhibit a minimum purity of 99%, as verified through comprehensive orthogonal analytical methodologies including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and Fourier-transform infrared spectroscopy (FTIR). This multi-technique validation approach ensures not only accurate quantification of the principal analyte but also definitive structural confirmation, distinguishing ADB-BUTINACA from related indazole-3-carboxamide synthetic cannabinoids such as ADB-INACA, ADB-BINACA, 5F-ADB, MDMB-BUTINACA, and other N-alkyl or tert-leucinamide derivatives.

Each shipment is accompanied by a batch-specific Certificate of Analysis (CoA) bearing a unique lot number, documenting the complete analytical profile including assay value, residual solvent analysis (compliant with ICH Q3C guidelines), and heavy metal content limits (typically <10 ppm for lead, cadmium, mercury, and arsenic). The CoA serves as an essential quality assurance document for laboratory managers during procurement validation and regulatory compliance audits, providing traceability from synthesis through final release testing. Certified reference materials for ADB-BUTINACA are available from suppliers such as Cayman Chemical (Product No. 29350) and LGC Standards (Product Code CAY-29350) with chromatographic purity ≥98%, underscoring the importance of high-purity standards for forensic and research applications.aklagare+3

The physical presentation of ADB-BUTINACA as a white to off-white crystalline powder offers distinct advantages for analytical flexibility: the compound presents as a microcrystalline or amorphous solid with consistent particle size distribution, facilitating rapid dissolution and homogeneous stock solution preparation in organic solvents. This powdered form enables precise gravimetric dispensing for custom concentration requirements in receptor-binding assays and mass spectral calibration protocols. The powder undergoes particle size analysis to confirm consistency across batches, a critical specification for quantitative analytical workflows requiring reproducible dissolution kinetics in forensic and pharmacological assays. ADB-BUTINACA has been reported as a crystalline solid with molecular formula C₁₈H₂₆N₄O₂ and molecular weight 330.43 g/mol.aklagare+3

This level of purity and physical uniformity is non-negotiable for reproducible, publishable research outcomes in forensic chemistry and NPS monitoring. Lower-grade industrial reagents, often lacking comprehensive CoA documentation or exhibiting purity below 98%, introduce unacceptable variability in retention time alignment, mass spectral fragmentation patterns, and quantitative calibration curves. For laboratories developing validated LC-MS/MS or GC-MS methods for indazole-3-carboxamide synthetic cannabinoid detection, only analytically characterised reference materials meeting 99% purity specifications can ensure method accuracy, precision, and regulatory acceptance.

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: ADB-BUTINACA serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used in forensic toxicology, workplace drug testing, and post-mortem analysis. The compound’s well-characterised fragmentation pattern under electron ionisation (EI) and electrospray ionisation (ESI) conditions enables definitive identification in complex biological matrices, supporting method validation for confirmatory testing protocols targeting 1-butyl-substituted indazole-3-carboxamide synthetic cannabinoids. European and USA forensic laboratories utilise ADB-BUTINACA reference standards for proficiency testing schemes and NPS monitoring programmes, ensuring analytical competency in detecting novel psychoactive substances within the indazole-3-carboxamide SCRA class. Validated MRM transitions for ADB-BUTINACA detection include the molecular ion [M+H]⁺ at m/z 331.2078 (exact mass for C₁₈H₂₇N₄O₂⁺) and characteristic butylindazole and tert-butylcarboxamide fragments, with molecular formula C₁₈H₂₆N₄O₂ and molecular weight 330.43 g/mol enabling precise mass detection in high-resolution mass spectrometry (HRMS) workflows. Detection limits in validated methods typically reach 0.5–2 ng/mL in urine, blood, and oral fluid matrices. ADB-BUTINACA and two of its metabolites, ADB-BUTINACA N-butanoic acid and ADB-BUTINACA N-(4-hydroxybutyl), are available as reference materials from commercial suppliers for use in forensic and clinical investigations.cdn.who+3

Cannabinoid Receptor Pharmacology: Within strictly controlled in vitro modelling frameworks, ADB-BUTINACA reference material supports receptor-binding affinity studies at cannabinoid receptors CB1 and CB2, as well as functional G-protein coupling assays using transfected cell lines expressing specific receptor subtypes. These investigations, conducted exclusively in accredited laboratory environments by qualified personnel, generate critical data on receptor binding affinity (Kᵢ values), functional potency (EC₅₀ values), and structure-activity relationships within the indazole-3-carboxamide synthetic cannabinoid class. ADB-BUTINACA is a potent CB1 agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC₅₀ of 6.36 nM for CB1. The 1-butyl substitution pattern on the indazole ring combined with the (S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl (tert-leucinamide) side chain confers distinct pharmacological properties compared to 1-benzyl (ADB-BINACA), 5-fluoropentyl (5F-ADB), or unsubstituted analogues, making it a valuable reference compound for dissecting N-alkyl chain length and steric effects on CB1/CB2 selectivity, biased agonism, and signal transduction pathways. All such applications must be performed within institutional frameworks (university, CRO, or pharmaceutical R&D) adhering to appropriate ethical and biosafety protocols.aklagare+2

Chemical Synthesis & Reaction Monitoring: As a high-purity 1-butyl-indazole-3-carboxamide, ADB-BUTINACA functions as a reference standard for monitoring synthetic transformations in medicinal chemistry programmes targeting cannabinoid receptor modulation. The 1-butyl-1H-indazole-3-carboxamide core combined with the (S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl side chain imparts distinct electronic and steric properties compared to 1-benzyl, 5-fluoropentyl, or N-pentyl analogues, making this compound valuable for structure-activity relationship (SAR) studies examining N-alkyl chain effects on receptor binding affinity, metabolic stability, and cytochrome P450 interactions. Analytical chemists employ ADB-BUTINACA as an internal standard for HPLC quantification of reaction intermediates in the synthesis of related indazole-3-carboxamide synthetic cannabinoids, leveraging its well-resolved chromatographic behaviour and UV absorption characteristics.aklagare+2

Method Validation & Calibration: ADB-BUTINACA powder provides a stable, accurately dosed source for constructing calibration curves in quantitative LC-MS/MS assays, with bulk powdered material enabling preparation of multiple stock solution aliquots at defined concentrations (e.g., 1mM in anhydrous methanol, acetonitrile, or DMF). The powdered form ensures consistent mass delivery across multiple preparations, reducing inter-assay variability in forensic and clinical toxicology laboratories analysing indazole-3-carboxamide synthetic cannabinoid samples. This application is strictly limited to in vitro analytical method development and validation, never extending to human or animal administration. Reference materials for ADB-BUTINACA are supplied as crystalline solids or 1 mg/mL solutions in methanol (CRM format) with molecular weight 330.4 g/mol and purity ≥98%.cdn.who+3

Compound Stability, Optimal Storage, and Safe Handling Protocols

ADB-BUTINACA, as a synthetic cannabinoid indazole-3-carboxamide, exhibits moderate susceptibility to oxidative degradation, photolytic decomposition, and hydrolytic degradation when exposed to ambient atmospheric conditions, light, and moisture. The 1-butyl substituent on the indazole ring confers baseline chemical stability, yet long-term integrity demands strict adherence to prescribed storage protocols.

Short-Term Storage (+4°C): For active laboratory use within 3–6 months, store ADB-BUTINACA powder in its original amber glass vials at +4°C (refrigerated conditions), protected from light and moisture. Ensure vials remain tightly sealed with desiccant packets intact, and ideally under inert atmosphere (nitrogen or argon) to prevent atmospheric moisture and oxygen from inducing degradation. Equilibrate vials to room temperature in a desiccator before opening to minimise condensation formation on the powder surface.

Long-Term Storage (-20°C or -80°C): For extended preservation beyond 6 months, transfer ADB-BUTINACA powder to -20°C (preferably -80°C for multi-year storage) in airtight, desiccated containers shielded from light and, ideally, under inert atmosphere. Under these conditions—sealed, desiccated, -20°C, protected from light, inert atmosphere—powdered ADB-BUTINACA maintains specification compliance for 24–36 months, as evidenced by stability data on analogous indazole-3-carboxamide reference standards. Avoid repeated freeze-thaw cycles by aliquoting powder into single-use vials before freezing.cdn.who+2

Safe Handling Prerequisites: All handling of ADB-BUTINACA powder must occur within a certified chemical fume hood, with personnel wearing appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a laboratory coat. The powdered form presents higher aerosolisation risk compared to pellets or crystals; avoid generating dust clouds during weighing or transfer operations. For stock solution preparation, ADB-BUTINACA demonstrates solubility in polar organic solvents including anhydrous methanol, ethanol, acetonitrile, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) to concentrations of 1–10mM or higher. Prepare solutions fresh or store as frozen aliquots at -20°C to prevent hydrolytic or oxidative degradation. Given the controlled substance status of ADB-BUTINACA and related synthetic cannabinoids in many jurisdictions (scheduled as a DEA Schedule I controlled substance in the USA, and controlled in multiple EU member states under NPS legislation), implement additional security protocols to prevent unauthorised access or diversion. ADB-BUTINACA is a DEA Schedule I controlled substance and may be subject to regulatory control in multiple jurisdictions.cdn.who+2

Technical Specifications and Molecular Attributes

Roid Chem Store: Your Premier EU Vendor for High-Purity Reagents

Roid Chem Store transcends the conventional supplier model, positioning itself as an indispensable partner in USA AND European scientific rigour for analytical chemists, forensic toxicologists, and cannabinoid pharmacologists. Our hypothetical ISO 9001-certified quality management system underpins every operational facet—from raw material sourcing through final batch release—ensuring consistent adherence to the stringent purity and documentation standards demanded by modern research.

Our dedicated logistics chain guarantees discreet, temperature-controlled shipping across all EU member states and the USA, with expedited delivery options for time-sensitive research programmes. Each shipment is packaged in compliance with international chemical transport regulations, utilising tamper-evident, light-shielded containers with integrated desiccant systems and, for sensitive compounds, inert atmosphere packaging to preserve compound integrity during transit. Given the DEA Schedule I controlled substance status of ADB-BUTINACA in the USA and controlled substance scheduling in multiple EU member states, all shipments include appropriate regulatory documentation and are restricted to licensed research facilities with valid institutional approvals (DEA registration, state controlled substance licenses, or EU equivalent).

Beyond logistics, Roid Chem Store distinguishes itself through expert customer support capable of discussing analytical specifications, CoA interpretation, and application-specific guidance for in vitro assay development. Our team comprises analytical chemists and regulatory specialists who understand the nuanced requirements of forensic indazole-3-carboxamide method validation, mass spectral library development, and cannabinoid receptor pharmacology. When you partner with Roid Chem Store, you gain access not merely to a chemical inventory, but to a comprehensive scientific resource committed to advancing the frontiers of laboratory research.